Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

Apoptosis stimulant

DRUG CLASS:

Apoptosis stimulant

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

‹

›

No biomarker	Chronic Myeloid Leukemia	No biomarker	Chronic Myeloid Leukemia	omacetaxine mepesuccinate Sensitive: A1 - Approval omacetaxine mepesuccinate Sensitive : A1	omacetaxine mepesuccinate Sensitive: A1 - Approval omacetaxine mepesuccinate Sensitive : A1
No biomarker	Small Cell Lung Cancer	No biomarker	Small Cell Lung Cancer	lurbinectedin Sensitive: A1 - Approval lurbinectedin Sensitive : A1	lurbinectedin Sensitive: A1 - Approval lurbinectedin Sensitive : A1
Chr t(15;17)	Acute Promyelocytic Leukemia	Chr t(15;17)	Acute Promyelocytic Leukemia	arsenic trioxide Sensitive: A1 - Approval arsenic trioxide Sensitive : A1	arsenic trioxide Sensitive: A1 - Approval arsenic trioxide Sensitive : A1
PML-RARA fusion	Acute Promyelocytic Leukemia	PML-RARA fusion	Acute Promyelocytic Leukemia	arsenic trioxide Sensitive: A1 - Approval arsenic trioxide Sensitive : A1	arsenic trioxide Sensitive: A1 - Approval arsenic trioxide Sensitive : A1
No biomarker	Glioma	No biomarker	Glioma	teserpaturev Sensitive: A1 - Approval teserpaturev Sensitive : A1	teserpaturev Sensitive: A1 - Approval teserpaturev Sensitive : A1
No biomarker	Ewing Sarcoma	No biomarker	Ewing Sarcoma	lurbinectedin Sensitive: A2 - Guideline lurbinectedin Sensitive : A2	lurbinectedin Sensitive: A2 - Guideline lurbinectedin Sensitive : A2
No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	pembrolizumab + quaratusugene ozeplasmid Sensitive: B - Late Trials pembrolizumab + quaratusugene ozeplasmid Sensitive : B	pembrolizumab + quaratusugene ozeplasmid Sensitive: B - Late Trials pembrolizumab + quaratusugene ozeplasmid Sensitive : B
No biomarker	Pancreatic Ductal Adenocarcinoma	No biomarker	Pancreatic Ductal Adenocarcinoma	atezolizumab + pelareorep Sensitive: B - Late Trials atezolizumab + pelareorep Sensitive : B	atezolizumab + pelareorep Sensitive: B - Late Trials atezolizumab + pelareorep Sensitive : B
No biomarker	Small Cell Lung Cancer	No biomarker	Small Cell Lung Cancer	atezolizumab + quaratusugene ozeplasmid Sensitive: B - Late Trials atezolizumab + quaratusugene ozeplasmid Sensitive : B	atezolizumab + quaratusugene ozeplasmid Sensitive: B - Late Trials atezolizumab + quaratusugene ozeplasmid Sensitive : B
No biomarker	Bladder Cancer	No biomarker	Bladder Cancer	Alpha1H Sensitive: B - Late Trials Alpha1H Sensitive : B	Alpha1H Sensitive: B - Late Trials Alpha1H Sensitive : B
IDH1 mutation	Glioblastoma	IDH1 mutation	Glioblastoma	NEO100 Sensitive: C2 – Inclusion Criteria NEO100 Sensitive : C2	NEO100 Sensitive: C2 – Inclusion Criteria NEO100 Sensitive : C2
BRCA2 mutation	Breast Cancer	BRCA2 mutation	Breast Cancer	lurbinectedin Sensitive: C2 – Inclusion Criteria lurbinectedin Sensitive : C2	lurbinectedin Sensitive: C2 – Inclusion Criteria lurbinectedin Sensitive : C2